Prospective Randomised Multicenter Study for Therapy Optimization of Recurrent, Progressive Low Grade Non-Hodgkin Lymphomas and Mantle Cell Lymphomas.

Trial Profile

Prospective Randomised Multicenter Study for Therapy Optimization of Recurrent, Progressive Low Grade Non-Hodgkin Lymphomas and Mantle Cell Lymphomas.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2015

At a glance

  • Drugs Bendamustine (Primary) ; Fludarabine; Rituximab
  • Indications Acute myeloid leukaemia; Follicular lymphoma; Lymphoma; MALT lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Dec 2015 Results published in the Lancet Oncology
    • 19 Oct 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
    • 19 Oct 2011 Additional lead trial center identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top